Sangamo Therapeutics, Inc (SGMO) insider trading
Every open-market stock purchase and sale by Sangamo Therapeutics, Inc executives, directors, large shareholders and members of Congress, from SEC Form 4 filings. Sector: Other.
Insider activity at a glance
- Insiders sold $107K over the last 12 months (2 sales). No open-market buys.
- Last insider buy: John Markels (Director), $25K, 4 years ago.
Last 12 months: insiders bought $0 (0 buys) and sold $107K (2 sales).
Recent SGMO insider trades
| Date | Insider | Trade | Value |
|---|---|---|---|
| May 25, 2026 | Sandy Macrae (CEO) | Sold (not open market) | $2.2K |
| May 25, 2026 | Nathalie Dubois-Stringfellow (C-suite exec) | Sold (not open market) | $703 |
| May 25, 2026 | Scott B. Willoughby (C-suite exec) | Sold (not open market) | $703 |
| May 25, 2026 | Nikunj Jain (Insider) | Sold (not open market) | $334 |
| May 25, 2026 | Gregory D Davis (Insider) | Sold (not open market) | $284 |
| Apr 22, 2026 | Gregory D Davis (Insider) | Sold | $17.7K |
| Apr 21, 2026 | Nathalie Dubois-Stringfellow (C-suite exec) | Sold | $89.2K |
| Apr 1, 2026 | Gregory D Davis (Insider) | Bought (not open market) | — |
| Apr 1, 2026 | Nathalie Dubois-Stringfellow (C-suite exec) | Bought (not open market) | — |
| Apr 1, 2026 | Sandy Macrae (CEO) | Bought (not open market) | — |
| Apr 1, 2026 | Scott B. Willoughby (C-suite exec) | Bought (not open market) | — |
| Apr 1, 2026 | Nikunj Jain (Insider) | Bought (not open market) | — |
| Feb 25, 2026 | Sandy Macrae (CEO) | Sold (not open market) | $15.8K |
| Feb 25, 2026 | Nathalie Dubois-Stringfellow (C-suite exec) | Sold (not open market) | $5.8K |
| Feb 25, 2026 | Scott B. Willoughby (C-suite exec) | Sold (not open market) | $5.8K |
| Feb 25, 2026 | Nikunj Jain (Insider) | Sold (not open market) | $2.4K |
| Feb 25, 2026 | Gregory D Davis (Insider) | Sold (not open market) | $2.4K |
| Feb 24, 2026 | Sandy Macrae (CEO) | Sold (not open market) | $2.5K |
| Feb 24, 2026 | Nathalie Dubois-Stringfellow (C-suite exec) | Sold (not open market) | $975 |
| Feb 24, 2026 | Scott B. Willoughby (C-suite exec) | Sold (not open market) | $780 |
| Feb 24, 2026 | Gregory D Davis (Insider) | Sold (not open market) | $393 |
| Feb 24, 2026 | Nikunj Jain (Insider) | Sold (not open market) | $315 |
| Jan 22, 2026 | Sandy Macrae (CEO) | Sold (not open market) | $41K |
| Jan 22, 2026 | Scott B. Willoughby (C-suite exec) | Sold (not open market) | $14.6K |
| Jan 22, 2026 | Nathalie Dubois-Stringfellow (C-suite exec) | Sold (not open market) | $14.6K |
Who's trading SGMO
- Scott B. Willoughby, VP: other filings, last May 25, 2026
- Gregory D Davis, Insider: sold $17.7K (1 sale), last May 25, 2026
- Nathalie Dubois-Stringfellow, C-suite exec: sold $89.2K (1 sale), last May 25, 2026
- Nikunj Jain, Insider: other filings, last May 25, 2026
- Sandy Macrae, CEO: other filings, last May 25, 2026
- Prathyusha Duraibabu, CFO: other filings, last Jan 22, 2026
Get free alerts when an insider at Sangamo Therapeutics, Inc files a new trade →